PresentationTerence FlynnEquity Analyst All right. Thanks. I think we're going to get started. But I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst. I'm very pleased to be hosting Bristol-Myers this morning. Joining us from the company, we have Chris Boerner, the company's CEO; and Adam Lenkowsky, the company's Chief Commercial Officer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, pleas ...